Technology
Health
Biotechnology

SELLAS Life Sciences

$0.1295
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0044 (-3.36%) Today
+$0.0029 (2.29%) As of 7:48 PM EDT after-hours

Why Robinhood?

You can buy or sell SLS and other stocks, options, ETFs, and crypto commission-free!

About SLS

SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutics for cancer indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. Read More Its products include galinpepimut-S and nelipepimut-S. The company was founded on April 3, 2006 and is headquartered in New York, NY.

Employees
8
Headquarters
New York, New York
Founded
2006
Market Cap
3.06M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
43.35M
High Today
$0.13
Low Today
$0.1208
Open Price
$0.1213
Volume
21.45M
52 Week High
$2.46
52 Week Low
$0.1021

Collections

Technology
Health
Biotechnology
Cancer Prevention
Medical
Biopharmaceutical
Pharmaceutical
US

SLS Earnings

-$0.40
-$0.33
-$0.27
-$0.20
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 14, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.